As the roles of various proteins within the human body become clearer, novel research can develop to produce effective therapies with a high specificity. In this video, Emery Bresnick, PhD, from the University of Wisconsin, Wisconsin, WI, speaking from the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Haematology (ESH), discusses the link between GATA2 and acute myeloid leukemia. Dr Bresnick touches upon the mechanism of action of the gene, the influence it has upon progenitor and stem cells, and the effects of coding and non-coding mutations of GATA2.
Author: Editor
To efficiently produce effective therapies, it is necessary for experts within different specialties to collaborate. At the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Haematology (ESH), Emery Bresnick, PhD, from the University of Wisconsin, Wisconsin, WI, discusses the benefits of utilizing a collaborative research method in hematology-oncology, referencing insightful examples to exemplify this approach.
Immunotherapy has emerged in recent years as a promising lymphoma treatment, with exciting new drug classes being developed with innovative mechanisms of action. Here, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses various types of lymphoma treatment, including ADCC-activating monoclonal antibodies, antibody-drug conjugates, and traditional immunotherapies such as PD-1 inhibitors. Dr Collins reviews the efficacy of these drug types in both Hodgkin and non-Hodgkin lymphoma, and some of their specific subtypes, drawing conclusions from a range of sources, including the 2002 study by the French GELA group regarding the effectiveness…
As the finer details of how therapies interact within the body become clear, novel research to create more effective medications can occur. At the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Haematology (ESH), Christoph Plass, PhD, from the German Cancer Research Center, Heidelberg, Germany, discusses the use of epigenetic therapies to tackle acute myeloid leukemia and myelodysplastic syndromes. Dr Plass highlights the potential molecular mechanisms that these drugs utilize to promote the apoptosis of leukemic cells, referencing LTRs and treatment-induced non-annotated TSSs.
To produce safe and effective therapies for patients, novel research must first occur in cell culture systems. In this interview, Christoph Plass, PhD, from the German Cancer Research Center, Heidelberg, Germany, discusses his teams research into epigenetic therapies and provides us with an overview of the numerous potential benefits of improved understanding of the molecular mechanism of these therapies, highlighting potential diagnostic and prognostic biomarker identification. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Haematology (ESH).
There are two well-known checkpoint inhibitors that have shown efficacy in relapses/refractory Hodgkin lymphoma, nivolumab and pembrolizumab, both PD-1 inhibitors. Here, John Kuruvilla, MD, FRCPC at the Princess Margaret Cancer Centre, Toronto, ON takes us through the existing data, such as efficacy, safety and remission rates. Recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada.
Francine Foss, MD, from the Yale University School of Medicine, New Haven, CT, discusses targeting chemokines at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada. Chemokines are a group of molecules that are expressed in the microenvironment of T- and B-cell malignancies. The anti-CCR4 antibody has been developed, and there is now research into whether there is a role for other chemokine therapy in lymphoma. There is also the possibility for targeting specific chemokines that affect the growth of the tumor cell to be targeted, as well as those associated with migration and metastasis.
“Both targeted agents, such as brentuximab vedotin, and checkpoint inhibitors, such as pembrolizumab, have shown activity in a subset of patients with cutaneous T-cell lymphoma. Francine Foss, MD at the Yale University, New Haven, CT is using this disease as a model to assess the efficacy and mechanism of action of combining targeted agents with checkpoint inhibitors. Recorded at the International Workshop of Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada.”
Dr. Jack West addresses the question of whether the data with various PD-1 and PD-L1 inhibitors in lung cancer management can be viewed as a class effect and whether these immune checkpoint inhibitors should be considered interchangeable.
Patients who are actively engaged with their diagnosis, treatment and symptoms now have an outlet to share their treatment journey and day-to-day experiences for research to help patients with MPNs. Hear Lindsey Whyte from the MPN Research Foundation, and Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center discuss how patients can contribute to the cancer community and scientific research by sharing their voice. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Neeraj Agarwal, MD Associate Professor of Medicine Director, Genitourinary Oncology Co-leader, Urologic Oncology Multidisciplinary Program Huntsman Cancer Institute, University of Utah discusses the treatment of metastatic renal cell carcinoma (mRCC) in the elderly at the 2017 Kidney Cancer Association symposium in Miami, FL.
Pavlos Msaouel MD, PhD Chief Fellow, Hematology/Oncology MD Anderson Cancer Center discusses Renal Medullary Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.
MOASC Educational Series 2017 roundtable discussion on oncology billing and the new challenges.
Remy Turner presents the options available to providers to follow-up on claims that have been submitted for payment. Timeliness and claim submission guidelines for follow-up forms will also be discussed.
Dawn Holcombe, MBA, FACMPE, ACHE DGH Consulting discusses Pharmacy Standards in transition and real at the MOASC Educational Series 2017
Elaine L. Towle, CMPE discusses MACRA and MIPS and an Oncology Billing Update: And Whats new for 2018? from the MOASC Educational Series November 9th, 2017.
Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for durvalumab immunotherapy in stage III NSCLC, and which will likely lead to some patients shifting away from surgery in favor of chemoradiation followed by durvalumab.
Christopher Wood, MD, Elizabeth Plimack, MD, Martin Voss, MD, Viraj Masters, MD, A. Ari Hakimi, MD consult on a several real world challenge kidney cancer cases at the 2017 Kidney Cancer Association symposium in Miami, FL.
Brian Shuch, MD Assistant Professor of Urology and Radiology Yale School of Medicine Genomic Heterogeneity and the Small Renal Mass discusses Genomic Heterogeneity and the Small Renal Mass at the 2017 Kidney Cancer Association symposium in Miami, FL.
Martin Voss, MD Memorial Sloan Kettering discusses Integrated Biomarker Analysis for 412 RCC patients Treated on the Phase 3 COMPARZ Trial at the 2017 Kidney Cancer Association symposium in Miami, FL.
Sumanta Kumar Pal, M.D City of Hope Cancer Center discusses IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.
Comparative Genomic Profiling of Matched Maria Becerra, MD discusses Primary and Metastatic Tumors in Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.
Vadim S. Koshkin, MD Cleveland Clinic Taussig Cancer discusses Clinical Activity of Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.
Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Endowed Professorship In Urology Department of Urology The University of Texas MD Anderson Cancer Center outlines Training Urologists To Be Experts In Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.
Ronald M. Bukowski, MD discusses Training Medical Oncologists to be Experts in RCC at the 2017 Kidney Cancer Association symposium in Miami, FL.
Martin Voss, MD Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center, New York gives an Update on Genomic Classifiers in RCC at the 2017 Kidney Cancer Association symposium in Miami, FL.
Joshua M. Lang, MD University of Wisconsin School of Medicine and Public Health discusses Circulating Biomarkers in Clear Cell Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.
Payal Kapur, M.D. Associate Professor of Pathology and Urology, UTSW Group Leader Genitourinary Pathology, UTSW Kidney Cancer Program co-leader, Simmons Cancer Center discusses In Vivo Models of RCC Genetically engineered mouse models in ccRCC at the 2017 Kidney Cancer Association symposium in Miami, FL.
Leigh Ellis Ph.D. Assistant Professor Department of Oncologic Pathology Dana-Farber Cancer Institute Brigham and Womens Hospital Harvard Medical School discusses 3-dimensional (3D) Organoids for Renal Cell Carcinoma Research at the 2017 Kidney Cancer Association symposium in Miami, FL.
Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery Affiliate Member Department of Computational Biology discusses Cell line and PDX models in renal cell carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.
Viraj A. Master of Emory University discusses Neoadjuvant Presurgical Therapy for RCC: Lessons Learned at the 2017 Kidney Cancer Association symposium in Miami, FL.
Tim Eisen University of Cambridge discusses Perspective(s) on Adjuvant Trials at the 2017 Kidney Cancer Association symposium in Miami, FL.
Grant D Stewart BSc, MBChB, FRCSEd (Urol), PhD University Lecturer and Consultant in Urological Surgery, Academic Urology Group, University of Cambridge discusses Prospective surgical RCC research: challenges, pitfalls and opportunities at the 2017 Kidney Cancer Association symposium in Miami, FL.
Axel Bex, MD, PhD The Netherlands Cancer Institute Amsterdam, The Netherlands outlines the Challenges in SURTIME and CARMENA at the 2017 Kidney Cancer Association symposium in Miami, FL.
Mark W. Ball, MD Staff Clinician | Assistant Research Physician Urologic Oncology Branch National Cancer Institute National Institutes of Health discusses Imaging in Renal Cell Carcinoma: Novel Methods and Approaches at the 2017 Kidney Cancer Association symposium in Miami, FL.
Steven C. Campbell, MD, PhD Program Director, Vice Chairman Department of Urology Center for Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic discusses Determinants and Predictors of Renal Function after Renal Surgery at the 2017 Kidney Cancer Association symposium in Miami, FL.
Rodolfo Borges dos Reis MD; PhD. Head of Uro-oncology Ribeirão Preto Medical School The University of São Paulo answers teh question Cystic Renal Masses: What are we Really Talking About? at the 2017 Kidney Cancer Association symposium in Miami, FL.
R. Houston Thompson, MD Professor of Urology Mayo Clinic, Rochester, MN @HThompsonMD presents Guidelines on Managing SRMs: Compare and Contrast at the 2017 Kidney Cancer Association symposium in Miami, FL.
John T. Leppert, MD MS Associate Professor, Stanford University Director of Urologic Oncology, VA Palo Alto @johnleppert presents Nephrometry: 21st Century Phrenology at the 2017 Kidney Cancer Association symposium in Miami, FL.
Loren Tarantino, MS SMP Global Partner discusses Systems Thinking Approach to Strategic Management at the MOASC educational series on November 8th, 2017.
Roberta Buell Principal, On Point Oncology presents the Revenue Cycle State of the State: Where are we? How can we fight delays and denials? at the MOASC educational series November 8th, 2017.
Elaine L. Towle, CMPE Division Director, Analysis & Consulting Services Clinical Affairs provides an in-depth look at the MACRA Quality Payment Program and notes that Its not too late to participate in 2017. Presentation was given at the MOASC educational series in Anaheim, CA on November, 8th 2017.
Merrianne Do, Pharm D of Walgreen’s discusses it’s new pilot program for specialty oncology drugs at the MOASC educational series in Anaheim CA on November 8th, 2017
Andrew W. Hahn, MD University of Utah Huntsman Cancer Institute @onchahn discusses Predictive genomic markers of response to VEGF targeted therapy (TT) in metastatic renal cell carcinoma (mRCC): Role of VHL and TP53 mutation, and FLT1 germline variant
IRINA PROSKOROVSKY, MSC discusses Axitinib and Cabozantinib in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis of AXIS and METEOR Trials at the 2017 Kidney Cancer Association symposium in Miami, FL.
Laurence Albiges, MD, PhD Institut Gustave Roussy Villejuif, France gives an overview of TiNivo A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.
Michael Roger Harrison, MD of Duke University presents Deferred Systemic Therapy (DST) for Metastatic Renal Cell Carcinoma: Preliminary Prospective Experience at the 2017 Kidney Cancer Association symposium in Miami, FL.
ALEXANDRA DRAKAKI, MD, PHD UNIVERSITY OF CALIFORNIA LOS ANGELES gives an overview of A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced Dendritic Cells in Patients with Metastatic Kidney Cancer at the 2017 Kidney Cancer Association symposium in Miami, FL.
Martin H. Voss, MD of Memorial Sloan Kettering outlines the DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo-controlled trial at the 2017 Kidney Cancer Association symposium in Miami, FL.
Paulo G. Bergerot, MD of City of Hope Comprehensive Cancer Center discusses Variations in treatment patterns for metastatic renal cell carcinoma mRCC between developing and developed countries at the 2017 Kidney Cancer Association symposium in Miami, FL.